Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.
C T2023-11-15T19:03:18-05:00July 30th, 2015|Categories: Blog|Tags: benchmark reports, comparative effectiveness, Cost Effectiveness Analysis, Dan Ollendorf, Emerging Therapy Assessment and Pricing, evidence-based medicine, Health Economic Models, health outcomes models, ICER, Institute for Clinical and Economic Review, Patti Peeples, Pharmaceutical Industry, Steve Pearson, tHEORetically Speaking|
Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
Tuesday, December 5, 2023
Sponsor: ICON
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
Friday, November 10, 2023
Sponsor: OpenHealth
Cell & Gene Therapies – Beginning with the End in Mind
Thursday, November 2, 2023
Sponsor: Magnolia Market Access
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication